The further improvement of therapeutic strategies expected in the next future will likely increase the survival of patients with HER2-positive early breast cancer, thus requiring the current version of PREDICT to be updated to provide reliable prognostic estimation in these patients. Here, ERBB2 is linked to breast cancer.